Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shyam Srivats"'
Autor:
Namrata S. Patil, Barzin Y. Nabet, Sören Müller, Hartmut Koeppen, Wei Zou, Jennifer Giltnane, Amelia Au-Yeung, Shyam Srivats, Jason H. Cheng, Chikara Takahashi, Patricia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William E. O’Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames
Publikováno v:
Cancer Cell. 40:289-300.e4
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from
Autor:
Dmitri Pchejetski, Caroline M. R. Low, Danielle Monteil, Heba Alshaker, Shyam Srivats, Qi Wang
Publikováno v:
Breast Cancer Research and Treatment
Purpose Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite recent ad
Autor:
J. Michael Edwardson, Colin W. Taylor, Gerard Vistal, Dilshan Balasuriya, Ruth D. Murrell-Lagnado, Shyam Srivats, Mathias Pasche
Publikováno v:
The Journal of Cell Biology
Sigma1 receptors inhibit store-operated Ca2+ entry and reduce the Ca2+ content of the intracellular stores. These effects are regulated by Sigma1 receptor ligands. A ligand-dependent interaction between Sigma1R and STIM1 reduces STIM1 association wit
Publikováno v:
Breast Cancer Research and Treatment
Purpose Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f47dc5fa3e04e07995c6faf227b3dcb
https://ueaeprints.uea.ac.uk/id/eprint/64323/
https://ueaeprints.uea.ac.uk/id/eprint/64323/
Publikováno v:
Biochemical and Biophysical Research Communications. 450:1452-1457
Unlike GluN2-containing N-methyl- d -aspartate (NMDA) receptors, which require both glycine and glutamate for activation, receptors composed of GluN1 and GluN3 subunits are activated by glycine alone. Here, we used atomic force microscopy (AFM) imagi
Autor:
Yimin Chao, Torsten Böhler, Colin Cooper, Heba Alshaker, Dmitri Pchejetski, Qi Wang, Shyam Srivats
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Many prostate cancers relapse after initial chemotherapy treatment. Combining molecular and chemotherapy together with encapsulation of drugs in nanocarriers provides effective drug delivery and toxicity reduction. We developed core shell lipid-polym
Publikováno v:
FEBS letters. 588(17)
Depletion of Ca2+ from the endoplasmic reticulum (ER) lumen triggers the opening of Ca2+ release-activated Ca2+ (CRAC) channels at the plasma membrane. CRAC channels are activated by stromal interaction molecule 1 (STIM1), an ER resident protein that
Autor:
Heba, Alshaker, Lysann, Sauer, Danielle, Monteil, Silvia, Ottaviani, Shyam, Srivats, Torsten, Böhler, Dmitri, Pchejetski
Publikováno v:
Advances in cancer research. 117
Sphingosine kinase 1 (SK1) is a lipid enzyme with oncogenic properties that converts the proapoptotic lipids ceramide and sphingosine into the antiapoptotic lipid sphingosine-1-phosphate and activates the signal transduction pathways that lead to cel
Publikováno v:
Pakistan journal of pharmaceutical sciences. 25(1)
In the present study, the effect of DG chloroform root extract was assessed on isolated rat heart and in-vitro antioxidant models. Ischemia reperfusion injury was experimentally induced by using Langendroff apparatus. The free radical scavenging pote
Autor:
Shivani Soni, Abhimanyu Paraskar, Sudipta Basu, Shiladitya Sengupta, Rituparna Sinha Roy, Nicola Lupoli, Shyam Srivats, Chitra Amarasiriwardena
The use of cisplatin, a first line chemotherapy for most cancers, is dose-limited due to nephrotoxicity. While this toxicity can be addressed through nanotechnology, previous attempts at engineering cisplatin nanoparticles have been limited by the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be6f30a2578333c0cb2c55f52333af6
https://europepmc.org/articles/PMC3158969/
https://europepmc.org/articles/PMC3158969/